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The present study was aimed at preparation of transdermal patches of tizanidine HCl, evaluation of 
the effect of polymers on in vitro release pattern of the drug, and the effect of permeation enhancers 
on the penetration of the drug through the rabbit skin. Various proportions of hydrophilic (HPMC) and 
hydrophobic (Eudragit L-100) polymers were used with PEG 400 as film-forming agent, and Span 20 
or DMSO as permeation enhancer. The formulations were assessed for physicochemical characteristics 
and in vitro drug release studies using USP paddle over disc method in phosphate buffered saline (pH 
7.4) at 32.0±1°C. On the basis of in vitro studies and physicochemical evaluations, S03-A and S04-A 
were selected at Eudragit : HPMC ratios of 8 : 2 and 7 : 3, respectively, for further ex vivo analysis. 
The effects of different concentrations of Span 20 and DMSO were evaluated on excised rabbit skin 
using Franz diffusion cell. Cumulative drug permeation, flux, permeability coefficient, target flux, and 
enhancement ratio were calculated and compared with the control formulations. Kinetic models and 
Tukey’s multiple comparison test were applied to evaluate the drug release patterns. Formulation SB03-
PE containing Eudragit L-100:HPMC (7:3) with Span 20 (15% w/w) produced the highest enhancement 
in drug permeation, and followed zero order kinetic model with super case-II drug release mechanism. 
Keywords: Ex-vivo permeation. Eudragit L100. Permeation enhances. Transdermal matrix patch. 
Monolithic system.
INTRODUCTION
Transdermal drug delivery systems (TDDS) are 
defined as self-contained, discrete dosage forms which, 
when applied to the intact skin, deliver the drug(s) through 
the skin at controlled rates to the systemic circulation 
(Shirsand et al., 2012). Transdermal drug products 
are intended to deliver therapeutic quantities of drugs 
systemically for the treatment or prevention of disorders 
at locations distant from the site of topical application. 
They have numerous merits over conventional drug 
delivery systems, including avoidance of hepatic 
first pass metabolism, reduction of pain, reduction in 
fluctuations in plasma drug levels, reduction of dosing 
frequency, ease of termination of therapy, and sustained 
release of drugs (Ali et al., 2016; Kumar, Philip, 2007). 
Notwithsatnding these advantages, transdermal passage 
of molecules is tedious due to the low permeability of 
the stratum corneum, the outermost layer of the skin. 
Indeed, a passive barrier is set up by different skin 
layers, a process which controls the permeation of 
drugs via the skin. Stratum corneum has a very high 
resistance to permeation and is the rate-controlling 
factor in percutaneous absorption. To overcome this 
passive barrier system, chemical penetration enhancers 
(CPEs) are used to lower the impermeability of the skin 
for a limited time, thereby facilitating the permeation of 
drugs through the skin (Williams, Barry, 2012; Pathan, 
Setty, 2009).
Tizanidine hydrochloride (TZD HCl) is a centrally-
acting skeletal muscle relaxant. It is an α2-adrenergic 
agonist, acting mainly at spinal and supraspinal levels 
to inhibit excitatory interneurones. It is used for the 
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symptomatic relief of spasticity associated with multiple 
sclerosis or with spinal cord injury, and also in the 
symptomatic treatment of painful muscle spasm (Kamen, 
Henney, Runyan, 2008). The oral bioavailability of TZD 
(Figure 1) is about 34 - 40%, with a half-life of 2 - 2.5 h. 
It undergoes rapid and extensive first-pass metabolism 
in the liver (about 95%) which leads to reduction in its 
bioavailability (Shanker et al., 2009). Studies on the 
effect of CPEs and sonophoresis on the transdermal 
flux of TZD HCl buffer solution across mouse skin 
revealed that most permeation enhancers, as well as 
low frequency ultrasound, were able to increase the 
permeation of TZD HCl through the skin (Mutalik et al., 
2009). Moreover, Sintov and Botner (2006) evaluated 
the potential transdermal delivery of diclofenac sodium 
using microemulsion system both in vivo and in vitro. 
It was found that topical administration of diclofenac 
microemulsion to rats resulted in 8-fold increase in 
plasma drug levels when compared to commerecially 
available Voltral gel®. In another study, Gratieri et al. 
(2014) demonstrated the iontophoretic delivery of 
Ketorolac® (a peripherally-acting muscle relaxant) from 
hydroxymethyl cellulose gel using porcine and human 
skin. Their study demonstrated that electrotransport 
of Ketorolac® was propotional to the current density 
and drug concentration in the gel. Many attempts have 
been made to increase the trandermal flux of different 
drugs using different techniques. Some of these have 
been mentioned in this section, and there are a number 
of available studies aimed at increasing the permeation 
of TZD HCl through the skin. However, there are no 
extant studies based on the use of transdermal patch 
formulations of TZD HCl.
The present study was carried out to prepare 
formulation of monolithic matrix type, sustained-release 
transdermal patch containing TZD HCl and CPEs. This 
was with a view to controlling drug release with increased 
drug permeation through the skin, and to achieve higher 
flux in order to improve patient compliance with reduced 
dosing frequency. The patches were evaluated for the 
principal effects of different concentrations of Eudragit 
(EL-100) and hydroxypropyl methylcellulose (HPMC) on 
drug release. The optimum formulations from in vitro drug 
release studies were further evaluated for the binary effect 
of dimethyl sulfoxide (DMSO) and sorbitan monolaurate 
(Span 20) as permeation enhancers in the permeation of 
TZD HCl through rabbit skin. 
MATERIAL AND METHODS
Material
Tizanidine hydrochloride (TZD HCl) was generously 
donated by English Pharma, Lahore Pakistan, while 
HPMC E-5, EL-100, polyvinyl alcohol (PVA) and PEG-
400 were purchased from Merck, Germany. Methanol 
was obtained from BDH, England. Span 20 and DMSO 
were procured from Daejung (Korea) and Fisher Scientific 
(Waltham, USA), respectively. All other chemicals and 
solvents used were of analytical grade, and were used 
without any need for further purification.
Methods
Preparation of Matrix type Transdermal Patches of 
TZD HCl
Transdermal patch of TZD HCl was formulated by 
solvent-casting technique. Accurately weighed amounts of 
HPMC and EL-100 were dissolved in 15 mL of methanol 
and mixed thoroughly for 30 minutes using a hot plate 
magnetic stirrer at 250 rpm. The drug was dissolved in 
5 mL of methanol and added to the polymeric solution 
with 40% w/w of PEG 400 as plasticizer. After complete 
mixing, the solution was sonicated for 20 min at 35 ᵒC 
to remove any bubbles. The formulation was then cast 
onto a petri-dish containing PVA (4% w/v) backing layer. 
An inverted funnel was placed over the petri-dish to 
control the rate of evaporation. The solvent was allowed 
to evaporate completely at room temperature for 48 h, 
and the separated patch was wrapped in aluminium foil, 
labeled properly and stored in a desiccator until further 
use (Table I). For the preparation of patches containing 
permeation enhancers, the casting solution was prepared 
by keeping the amount of polymer and drug constant and 
varying the amount of permeation enhancers. Permeation 
enhancer was added along with plasticizer in the drug-
polymer solution (Table II). A calibration curve was 
constructed from serial dilution of stock solution. Different 
dilutions were prepared, filtered and read at 319 nm in a 
FIGURE 1 - Chemical structure of tizanidine HCl (MW = 290.17 
Da, pKa = 7.4, Log p = 2.02, t1/2 = 2.25 hour).
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UV spectrophotometer. A regression line equation with 
a correlation coefficient (R2) was then constructed using 
Graph Pad Prism® :
y = mx+b
where m (slope) = 0.0367, b (y-intercept) = 0.0288 and R2 
(regression coefficient) = 0.9995.
Physicochemical evaluation of transdermal 
patches containing TZD HCl
Weight variation
Patches (n = 3) were weighed individually on digital 
weighing balance and the mean weight and standard 
deviation were calculated using MS Excel (El-Gendy et 
al., 2008).
TABLE I - Composition of different transdermal formulations containing TZD HCl without permeation enhancers
Formulation EL 100 (mg) HPMC E-5 (mg) TZD HCl (mg) PEG 400 (40%w/w) Methanol (mL)
S01-A 1000 - 4 400 20
S02-A 900 100 4 400 20
S03-A 800 200 4 400 20
S04-A 700 300 4 400 20
S05-A 600 400 4 400 20
S06-A 500 500 4 400 20
S07-A 400 600 4 400 20
S08-A 300 700 4 400 20
S09-A 200 800 4 400 20
S10-A 100 900 4 400 20
S11-A - 1000 4 400 20
EL100: Eudragit L100; HPMC: Hydroxypropyl methyl cellulose E-5; TZD HCl: Tizanidine hydrochloride; PEG 400: Polyethylene 
glycol 400
TABLE II - Composition of different transdermal formulations of TZD HCl containing permeation enhancers
Formulation EL 100: HPMC TZD HCl (mg) Methanol (mL) Penetration enhancer
SA01-B (Control) 8:2 2 20 -
SB01-B (Control) 7:3 2 20 -
SA01-PE 8:2 2 20 Span 20 (5%)
SA02-PE 8:2 2 20 Span 20 (10%)
SA03-PE 8:2 2 20 Span 20 (15%)
SA04-PE 8:2 2 20 DMSO (5%)
SA05-PE 8:2 2 20 DMSO (10%)
SA06-PE 8:2 2 20 DMSO (15%)
SB01-PE 7:3 2 20 Span 20 (5%)
SB02-PE 7:3 2 20 Span 20 (10%)
SB03-PE 7:3 2 20 Span 20 (15%)
SB04-PE 7:3 2 20 DMSO (5%)
SB05-PE 7:3 2 20 DMSO (10%)
SB06-PE 7:3 2 20 DMSO (15%)
*PEG 400 (40% w/w) as plasticizer. Span 20: Sorbitan monolaurate; DMSO: Dimethylsulfoxide; PE: Permeation enhancer
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Thickness
Thickness of the transdermal patch (n = 3) was 
estimated with a vernier caliper. The average thickness 
and standard deviation were calculated using MS Excel 
(El-Gendy et al., 2008).
Swelling index, percentage weight increase and 
erosion studies
Films of 1x1 cm were cut from the patch (n=3), 
fixed on pre-weighed cover slips and weighed on digital 
weighing balance. They were then placed in appropriately 
labeled petri-dishes and completely immersed in distilled 
water. At specified time intervals, the cover slips were 
taken out, blotted to remove excess of liquid and 
immediately weighed. If the films showed disintegration 
or began to dissolve, the experiment was discontinued. 
The swelling index and percentage weight increase due 
to swelling were calculated from the following formula 
(Pichayakorn et al., 2012):
Swelling Index = (W2 – W1)/ (W1)
Weight increase due to swelling (%) = (W2 - W1)/ (W1) x 
100
where W1 is initial weight of the film before swelling/ 
erosion, and W2 is weight of the film after time t.
The percentage erosion was estimated after 60 min 
of study and calculated using the formula (Pichayakorn 
et al., 2012):
Weight decrease due to erosion (%) = (W1 – W2)/ (W1) x 
100
Content uniformity test
A film of 2 x 2 cm of each formulation was cut from 
a patch (in triplicate), and completely dissolved in 100 
mL of PBS (pH 7.4) on a hot plate magnetic stirrer preset 
at 32 °C. A sample of 3 mL was taken through syringe 
filters, diluted with an equal volume of fresh PBS and the 
absorbanace was read spectrophotometrically at 319 nm. 
The amount of drug was estimated by extrapolation from 
the calibration curve.
Percentage moisture content
Triplicate samples of 1 x 1 cm film were weighed 
individually and stored in a desiccator containing silica 
beads at 25 °C. The films were weighed for five days 
until constant weights resulted. The percentage moisture 
content was calculated as outlined previusly (Janardhanan, 
Ramachandra, Rajappan, 2007):
Moistue content (%) = (W1 – W2)/ (W1) x 100
Percentage moisture uptake
Triplicate samples of 1 x 1 cm film were weighed 
individually and stored in a desiccator containing 200 mL 
of saturated solution of potassium chloride (KCl) at 25 °C 
for 84% RH. The films were weighed for five days till 
constant weight was achieved. The percentage moisture 
uptake was calculated viz: 
Moistue uptake (%) = (W2 – W1)/ (W2) x 100
(Limpongsa, Umprayn, 2008).
Water vapor transmission rate (WVTR)
A 1x1 cm film was cut in triplicate and placed 
separately in 5-mL vials containing 1 g of calcium 
chloride (CaCl2). The vials were weighed individually 
and kept in a desiccator at 25 °C containing 200 mL 
saturated solution of KCl for 84% RH. The vials were 
weighed for five days until constant weights were 
obtained. Then, WVTR was calculated using the formula 
of Jaydatt, Sreenivas (2013):
WVTR = (W2 – W1)/ (Time x Area) x 100
Water vapor permeability (WVP)
Triplicate samples of 1 x 1 cm of known thickness 
and weight were individually fixed in 5-mL vials 
containing silica beads as desiccant. The vials were 
weighed individually and kept in an incubator containing 
saturated solution of KCl at 30 °C. Then, they were were 
weighed for 24 h, and the WVP was calculated as indicated 
by Xiangrong et al. (2007):
P = (Q x d)/ [A x R x S (R1 – R2)]
where P is permeability, Q is amount of water vapor 
absorbed (in mg) at time t (h), d is film thickness (cm), 
A is area (cm2), S is saturated water vapor pressure at the 
test temperature (Pa), R1 is relative humidity (RH) in the 
chamber (84%), and R2 is relative humidity (RH) inside 
the vial (0%)
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In vitro drug release studies of matrix transdermal 
patches of TZD HCl
In vitro drug release studies (n = 3) were done in USP 
apparatus V, paddle over disc, in 500 mL of PBS (pH 7.4) 
at 32.0 ± 1 °C at 50 rpm. The sample (3 mL) was taken 
at suitable time intervals over a period of 12 h, filtered, 
diluted appropriately and read spectrophotometrically 
at 319 nm (Prabhakar et al., 2012). The percentage drug 
release was estimated with reference to the calibration 
curve.
Ex vivo skin permeation studies
Preparation of rabbit skin
Approval for the ex vivo permeation studies on 
rabbit skin was obtained from Animal Ethics Committee 
(Ref. No. IAEC-2015-06A), Faculty of Pharmacy, The 
University of Lahore, Lahore, Pakistan. The rabbit was 
sacrificed by cervical dislocation and a hairless abdominal 
region was obtained. The epidermis was prepared by 
soaking the skin in water at 60 °C for 45 sec. The sub-
dermal tissues were removed with forceps and the 
inner dermis side was wiped with a cotton swab dipped 
in isopropyl alcohol to remove adhering fats from its 
surface (Xi et al., 2010). The skin then was washed with 
warm distilled water, kept in saline solution and stored in 
refrigerator. It was used within one week of preparation. 
Before starting the experiment, the skin was allowed to 
attain room temperature for at least 10 h, and equilibrated 
for 1 h in PBS (pH 7.4) (Prabu et al., 2012). 
Ex vivo permeation studies using Franz diffusion cell
The ex vivo permeation study was conducted in 
a Franz diffusion cell with a diffusion area of 1.2 cm2 
using a receptor compartment volume of 12 mL. The 
dermal side of the skin was placed facing the receptor 
compartment. A circular transdermal patch (n = 3) was 
pressed on the skin, with backing layer side facing 
away from the stratum corneum. After securing the cell 
assembly with a clamp, the receptor compartment was 
filled with PBS (pH 7.4) maintaining sink conditions. The 
system was connected to a thermostatically controlled 
water bath to maintain the temperature at 32 ± 2 °C by 
circulating the water through a jacket surrounding the cell 
body (Xi et al., 2010). After every hour, a sample of 0.5 
mL was withdrawn from the receptor compartment and 
replaced with an equal volume of fresh PBS. The sample 
was diluted with appropriate volume of fresh buffer and 
the absorbance was read spectrophotometrically. The 
percentage drug release was estimated with reference to 
the calibration curve.
DATA ANALYSIS
Kinetic modeling of drug release from TDZ HCl 
transdermal patches
After in vitro drug release and ex vivo permeation of 
TZD HCl, mathematical models were used to determine 
the kinetics of drug release from the transdermal patches. 
The various kinetic models applied to the data were zero-
order, first order, and Higuchi and Korsmeyer-Peppas 
model. These models are described below (Siepmann, 
Peppas, 2012):
Zero-order model
To study the zero-order release kinetics, data 
obtained from in vitro and ex vivo drug release studies 
were plotted as cumulative amount of drug release against 
time. The release of the drug from the dosage form after 
the dissolution can be expressed as:
Qo – Qt = Kot
where Qt is the amount of the drug dissolved in time t, Qo 
is the initial amount of drug in the solution, and Ko is zero 
order release constant expressed as concentration/time
First order model
To study the first order release kinetics, data 
obtained from the in vitro drug release and Franz 
cell diffusion studies were plotted as log cumulative 
percentage of drug remaining against time. The release 
of the drug which follows first order release kinetics can 
be expressed as:
log C = log Co –kt/ 2.303,
where k is the 1st order rate constant expressed in time-1’, 
Co is initial concentration of the drug, and t is time.
Higuchi model
To study the Higuchi model, data obtained from 
in vitro drug release study and ex vivo permeation were 
plotted as cumulative percentage drug release against the 
square root of time. A simplified Higuchi model can be 
described as:
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Q = KH x t1/2
where KH is Higuchi dissolution constant, and Q refers to 
amount of drug release in time t.
Korsmeyer Peppas model
Data obtained from in vitro drug release study and 
skin permeation studies were plotted as log cumulative 
percentage drug release against log time. This can be 
represented vis:
Mt/ M∞ = Ktn
where Mt/ M∞ refers to the fraction of drug released at time 
t, Mt is total amount released at time t, M∞ is total amount 
of drug present in the patches, T is release time in hours, K 
is kinetic constant, and n is the release exponent indicative 
of the operating release mechanism.
Analysis of data obtained from ex vivo 
permeation studies
The ex vivo skin permeation studies were fitted into 
kinetic models as stated above. Data was also analyzed 
for cumulative amount of drug permeated (µg/cm2), target 
flux (µg/cm2h) for TZD HCl, drug flux (µg/cm2h) and 
permeability coefficient (cm/h).
The cumulative amount of drug permeated (µg/cm2) 
through the skin was plotted against time, and drug flux 
(µg/cm2h) at steady state was calculated by dividing the 
slope of the linear portion of the curve with the area of 
exposed skin surface. The permeability coefficient (cm/h) 
was derived by dividing the flux obtained from initial drug 
load. The enhancement ratio was estimated by dividing the 
flux of patch containing permeation enhancer to the flux 
of control patch (Shabbir et al., 2016).
STATISTICAL ANALYSES
One-way ANOVA by Tukey’s multiple comparison 
tests (at 95% confidence interval) for drug permeated (%) 
and flux (µg/cm2h) was estimated by Minitab® 17.1.0. 
Tukey’s post hoc pairwise comparisons were performed 
to compare factors which led to significant differences 
(Shabbir et al., 2016). 
RESULTS AND DISCUSSION
Physicochemical Evaluations
Weight variation
The weight of the formulated patches varied from 
1.6031± 0.0311 to 1.6909±0.0153 g (Table III). The 
low values of the SD indicate that the weight variability 
within a formulation was minimal and was reproducible. 
A relatively higher weight is attributed to the presence of 
the backing layer (Shabbir et al., 2017).
Thickness
The thickness of the patches ranged from 0.62 ± 0.02 
to 0.75 ± 0.02 cm (Table III), and the low SDs signify that 
the process employed was capable of reproducing films with 
minimal variability (Shabbir et al., 2017; Ali et al., 2016).
TABLE III - Results for weight variation, thickness, swelling index, percentage weight increase due to swelling and percentage 
erosion of transdermal patches of TZD HCl
Formulations Weight ± S.D. (mg)
Thickness ± S.D. 
(cm) Swelling index
Percentage weight 
increase
Percentage 
Erosion
S01-A 1.63 ± 0.068 0.75 ± 0.02 0.701 70.69 2.25
S02-A 1.63 ± 0.014 0.74 ± 0.01 0.83 82.99 4.12
S03-A 1.68 ± 0.003 0.71 ± 0.02 0.98 97.78 4.92
S04-A 1.64 ± 0.020 0.71 ± 0.01 1.29 129.08 6.53
S05-A 1.62 ± 0.048 0.64 ± 0.01 1.39 138.61 4.36
S06-A 1.68 ± 0.054 0.73 ± 0.02 1.47 147.19 4.23
S07-A 1.69 ± 0.015 0.64 ± 0.02 1.49 148.94 7.73
S08-A 1.67 ± 0.001 0.72 ± 0.02 1.69 169.42 6.03
S09-A 1.63 ± 0.009 0.62 ± 0.03 2.26 225.74 6.48
S10-A 1.68 ± 0.067 0.67 ± 0.02 Disintegrated after 10 min
S11-A 1.60 ± 0.031 0.62 ± 0.02 Disintegrated after 10 min
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Swelling index and percentage weight change due to 
swelling
As shown in Table III, the swelling index and 
percentage weight increase were minimum in S01-A (0.71 
and 70.69%, respectively) and maximum in S09-A (2.26 
and 225.74% respectively). The films S10-A and S11-A 
disintegrated after 10 minutes since they had maximum 
amount of hydrophilic polymer (HPMC). The swelling 
index depicts the hydration of film when it is immersed 
in water. Increased hydration of polymer in a film leads to 
the formation of empty spaces which may affect sustained 
release profile of matrix patch. In addition, the patch becomes 
less resistant to mechanical stress (Perioli et al., 2009).
The percentage erosion of the formulated patches 
was calculated to estimate the weight loss or disintegration 
after they had been immersed in water for 60 minutes. 
As the amount of EL-100 was increased, the rate of 
disintegration or erosion decreased because of the 
hydrophobic nature of polymer. Erosion was least in 
S01-A (2.25%) (Table III).
Drug content and content uniformity
The percentage drug content is shown in Table IV. 
The low value of SD is an indication of uniformity of 
drug content in different parts of the film. This ensures 
that the rheological properties of the casting solution 
are suitable for homogeneous distribution of drug in the 
film. For sustained release formulations, the drug should 
be distributed throughout the patch homogeneously and 
uniformly (Ali et al., 2016).
Percentage moisture content
The percentage moisture content varied from 2.88 
to 9.87% (Table IV). Formulation S01-A showed the 
lowest moisture content, whereas S11-A showed the 
highest content of moisture. It was observed that as the 
concentration of HPMC increased, the amount of moisture 
content also increased. This is due to the fact that HPMC 
is hydrophilic in nature, and so absorbs moisture from the 
atmosphere (Ammar et al., 2009). The acceptable amount 
of moisture in a patch is higher than 2% but less than 10%. 
This prevents the patch from becoming brittle and bulky, 
and reduces its susceptibility to microbial contamination 
(Ali et al., 2016). 
Percentage moisture uptake
Formulation S01-A showed the least moisture 
uptake, while S11-A had maximum moisture uptake 
capacity (Table IV). As the concentration of HPMC 
increased the moisture uptake capacity of the film also 
increased due to the hydrophilic nature of HPMC. On 
the other hand, EL-100 is hydrophobic but still possesses 
some hydrophilicity due to the presence of quaternary 
ammonium groups in its structure. Thus, formulations 
containing higher concentration of EL-100 are able to 
absorb moisture from the atmosphere at higher humidity. 
The presence of PEG 400, a hydrophilic substance, further 
increases the moisture uptake capacity of the films (Eva, 
Milan, 2012). It makes the network of polymers less dense 
because of increase in the mobility of polymeric chains 
TABLE IV - Results for moisture content, moisture uptake, water vapor transmission rate (WVTR) and water vapor permeability 
(WVP) of transdermal patches of TZD HCl
Formulation Moisture content (%)
Moisture 
uptake (%)
WVTR 
(g/m2.h)
WVP 
(mg.Pa-1.cm-1.h-1)
Drug content 
(%)
S01-A 2.88 4.49 4.34 x 10-6 8.89 x 10-7 100.12 ± 0.01
S02-A 2.89 5.12 4.35 x 10-6 9.15 x 10-7 99.22 ± 0.05
S03-A 2.93 5.50 4.41 x 10-6 9.47 x 10-7 100.06 ± 0.02
S04-A 4.89 8.67 4.35 x 10-6 9.02 x 10-7 99.08 ± 0.02
S05-A 5.85 9.06 4.54 x 10-6 9.21 x 10-7 97.30 ± 0.02
S06-A 5.53 9.54 4.44 x 10-6 9.70 x 10-7 98.20 ± 0.08
S07-A 5.84 9.22 4.44 x 10-6 9.84 x 10-7 97.90 ± 0.05
S08-A 5.73 11.03 4.38 x 10-6 9.91 x 10-7 99.78 ± 0.04
S09-A 5.81 11.99 4.50 x 10-6 9.61 x 10-7 100.28 ± 0.10
S10-A 7.61 11.72 4.43 x 10-6 9.73 x 10-7 97.89 ± 0.02
S11-A 9.87 16.91 4.63 x 10-6 9.92 x 10-7 99.04 ± 0.10
WVTR: Water vapor transmission rate; WVP: Water vapor permeability
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which increases the free volume between the matrix 
systems. This pore formation increases the absorption 
of water molecules into the film, resulting in increased 
porosity (El-Gendy et al., 2008). Moisture uptake studies 
are used to estimate the maximum amount of moisture 
a patch can hold when it is exposed to high humid 
conditions. For transdermal patches, moisture uptake up 
to 15% w/w is thought to prevent film bulkiness, thus 
avoiding discomfort (Ubaidulla et al., 2007).
Water vapor transmission rate (WVTR)
Maximum WVTR was seen in S11-A (4.63 x 10-6 
g/m2. h), while WVTR was least in S01-A (4.34 x 10-6 
g/m2.h, Table IV). This parameter (WVTR) serves to 
estimate the passage of vapors through a patch per unit 
area per unit time, so to ensure its integrity during storage 
(Xiangrong et al., 2007).
Water vapor permeability (WVP)
The lowest WVP was observed in S01-A (8.89 x 
10-7 mg.Pa-1.cm-1.h-1), while the highest value was seen in 
S11-A (9.92 x 10-7 mg.Pa-1.cm-1.h-1, Table IV). The high 
permeability of water through S11-A is due to the high level 
of HPMC in the formulation. The WVP is a parameter that 
determines the onset of drug release and drug release rate 
during dissolution (Xiangrong et al., 2007).
In vitro drug release studies
In vitro drug release from formulations containing single 
polymer
The percentage drug release was estimated with 
reference to the calibration curve (R2 = 0.9995). Drug 
release from formulations containing EL-100 (S01-A) and 
HPMC (S11-A) in maximum ratio is shown in Figure 2. 
It is evident from the in vitro release studies that 94.4% 
drug was released in 12 h from S01-A, whereas 99.0% 
of drug was released from SII-A within the third hour of 
dissolution. The relative hydrophobic nature of EL-100 
decreased its affinity for water, resulting in decreased 
thermodynamic activity of the drug in film, and decreased 
drug release. Due to its higher hydrophilic nature, HPMC 
absorbs water. Dissolution of an aqueous soluble fraction 
of polymer matrix leads to the swelling of the polymer, 
resulting in a faster release of drug from the pores of 
film because of adequate porosity and diffusivity. The 
formation of such pores decreases the mean diffusion path 
length of the drug molecules into the dissolution medium 
(Ansari, Singhai, Saraogi, 2011). 
It appears that EL-100 is a better release retardant 
at higher concentrations than HPMC. The addition of 
hydrophilic component to a patch enhances its release 
rate because HPMC is more permeable to water. It has 
been shown that release rate and permeation rate can be 
controlled for a long period of time by using a combination 
of lipophilic polymer and hydrophilic polymer (Ansari, 
Singhai, Saraogi, 2011). The in vitro drug release profile of 
S01-A (R2 = 0.9728) best fitted in Higuchi model. The drug 
release mechanism was found to be anomalous (non-Fickian 
diffusion) i.e. combination of diffusion and erosion.
Formulations containing combination of HPMC and EL 
100 in different ratios
The in vitro drug release profile of formulations S02-A 
to S10-A is depicted in Figure 2. Initially, there was a rapid 
release of drug from the transdermal patches containing 
higher proportion of HPMC. This rapid drug release (burst 
effect) is attributed to the hydrophilic nature of HPMC (Arora, 
Mukherjee, 2002). The addition of hydrophilic components 
to a formulation tends to enhance its release-rate constants, 
resulting in the leaching of hydrophilic polymeric matrix. 
This leads to the formation of pores in the matrix system 
(Darwhekar, Jain, Patidar, 2011). Burst effect was lowest 
in formulation S04-A, relative to the other formulations 
because of the higher concentration of EL-100 and lower 
HPMC concentration. No burst effect was evident in S02-A 
and S03-A because of the presence of high proportions 
of hydrophobic polymer. By decreasing the hydrophilic 
polymer, and increasing the hydrophobic portion of the 
FIGURE 2 - In vitro drug release (%) from TZD HCl transdermal 
patch containing EL100 and HPMC at different ratios. S01-A 
and S11-A contained EL100: HPMC at a ratio of 10:0 and 0:10 
respectively. The results are expressed as mean ± S.D, n=3.
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polymer matrix, the rapid drug release effect was gradually 
reduced, and sustained effect gradually increased. A 3-D 
surface plot (Figure 3) of formulations at t10 showed that 
as the concentration of HPMC increased, drug release 
from the matrix patch also increased, whereas a decrease 
in release rate was observed with an increase in EL-100 
concentration (Kusum et al., 2003). The values obtained 
from formulations S02-A, S03-A, S04-A, S05-A, S06-A and 
S08-A (with correlation constants of R2 of 0.9694, 0.9662, 
0.9831, 0.9896, 0.9748 and 0.9065, respectively) best fitted 
the Higuchi model. This signifies that the main drug release 
mechanism was diffusion, because proportionality between 
cumulative percentage drug release and square root of time is 
usually regarded as an indicator of diffusion-controlled drug 
release (Siepmann, Peppas, 2012). All other formulations did 
not fit into any kinetic model because their R2 values were 
too small. The values ‘n’ of Korsmeyer-Peppas equation 
depicted that drug release mechanism from transdermal 
patches S01-A to S04-A (with ‘n’ values of 0.78, 0.85, 0.78 
and 0.64 respectively) occurred via anomalous diffusion 
because the value of ‘n’ was greater than 0.5 but less than 1. 
Formulations S05-A to S11-A (with ‘n’ values 0.44, 0.39, 
0.14, 0.28, 0.21, 0.10 and 0.07, respectively) showed Fickian 
diffusion drug release mechanism (Siepmann, Peppas, 
2012). Ex vivo permeation studies were performed for the 
optimized formulations S03-A and S04-A which were 
selected according to the in vitro drug release profile data and 
physicochemical evaluation.
Ex vivo permeation studies
Ex vivo permeation of transdermal patches without 
penetration enhancer (control patches)
The cumulative amount of drug permeated from 
SA01-B and SB01-B is given in Figure 4. Although patch 
SA01-B (R2 = 0.9772) followed Higuchi model, only 
20.3% of the drug permeated from the matrix system to 
the skin after 12 h. When compared to SA01-B, permeation 
increased by a factor of 1.58 in SB01-B. Patch SB01-B 
with R2 value of 0.9897 followed zero order kinetic 
model. According to Korsmeyer-Peppas equation, the 
patch showed anomalous drug release and permeation, 
favoring both swelling and diffusion (Costa, Sousa, 2001). 
Flux rate also increased from 23.20 µg/cm2h in SA01-B, 
to 39.40 µg/cm2h in SB01-B (Table V). The increase in 
permeation rate was due to the increase in concentration 
of hydrophilic polymer HPMC. Although there was an 
increase in cumulative drug permeation, the two patches 
failed to achieve the desired target flux over a period of 
12 hours. Therefore, a penetration enhancer was required 
to improve the drug flux.
As the concentration of Span 20 increased from 5 
to 15% w/w in a formulation containing 8 : 2 (EL 100 : 
HPMC) drug polymer matrix, the cumulative amount of 
drug permeated also increased (Figure 4). Patches SA01-
PE and SA03-PE with R2 values of 0.9749 and 0.9833 
respectively, followed Higuchi model which signified a 
diffusion-controlled drug release and permeation. On the 
other hand, SA02-PE (R2 = 0.9705) fitted better in zero 
order kinetics. This permeation profile indicated that 
the drug-polymer matrix ensured constant concentration 
and was independent of the initial concentration. 
According to the ‘n’ value of Korsmeyer-Peppas equation, 
SA01-PE, SA02-PE and SA03-PE (n = 1.03, 1.12, and 1.03, 
respectively) had super case II transport mechanism in 
which polymer relaxation on imbibition of water is the 
rate controlling step (Siepmann, Peppas, 2012). Increases 
in flux were also observed with increases in permeation 
enhancer concentration (Table V). 
FIGURE 3 - Ex vivo cumulative drug permeated (µg/cm2 h) from 
TZD HCl patches containing permeation enhancers. SA01-B 
and SB01-B represents the control patches (without permeation 
enhancers). The results are expressed as mean ± SD, n=3.
FIGURE 4 - 3-D plot of in vitro drug release study of formulations 
at t10.
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The cumulative amount of drug permeated from 
formulations containing EL 100 and HPMC at a ratio of 
7:3, with Span 20 is shown in Figure 4. It is clear that as the 
concentration of Span 20 increased from 5 to 15% (w/w), 
the percentage permeation of drug also increased from 
363.44 to 902.94 µg/cm2. When fitted in various models 
SB01-PE, SB02-PE and SB03-PE (R2 = 0.9905, 0.9794, and 
0.9863, respectively) followed zero order kinetics. The 
‘n’ value of Korsmeyer-Peppas equation was greater 
than 1, indicating super case II transport drug release and 
permeation mechanism, possibly due to swelling and 
chain disentanglement of hydrophilic polymer. The flux 
of patches containing 15% (w/w) Span 20 was greater 
than formulations containing 5 and 10% (w/w) Span 20 
(Table V). 
The cumulative amount of drug permeated from the 
matrix patch increased with increase in the concentration 
of HPMC and Span 20. The hydrophilic property of 
HPMC contributed to increases in the penetration of 
solvent molecules into the polymeric matrix. This 
disturbed the compactness of the system, leading to the 
formation of pores and faster release and permeation of 
drug (Patel et al., 2009). The presence of PEG 400 further 
increased the permeation rate and made the network less 
dense due to increased mobility of the polymeric chain 
which caused the polymer to relax. Span 20 is a non-ionic 
surfactant that is considered to be the safest enhancer in 
relation to anionic, cationic and zwitterionic surfactants 
(Williams, Barry, 2012). It acts as a penetration enhancer 
by increasing the fluidity of the lipid components of 
stratum corneum through solubilization. It also interacts 
and binds with keratin filaments which cause disruption 
of corneocytes. Statistical analysis using one-way 
ANOVA and Tukey’s multiple comparison tests revealed a 
significant difference in drug permeation rate at t10 and flux 
(p < 0.001) at different Span 20 concentrations (Shabbir 
et al., 2016).
An increase in cumulative drug penetration was seen 
as DMSO concentration was increased in the 8 : 2 (EL 100 
: HPMC) polymer matrix system, with drug permeation 
values of 667.52, 826.92, and 1010.84 µg/cm2 at 5, 10 and 
15% (w/w) DMSO, respectively (Figure 4). Formulation 
SA04-PE (R2=0.9876) followed zero order kinetics 
whereas SA05-PE and SA06-PE (R2 = 0.9839 and 0.9119, 
respectively) appeared to follow Higuchi model. The 
values of ‘n’ for SA04-PE and SA05-PE in the Korsmeyer-
Peppas equation were 1.15 and 1.07, respectively, which 
implies super case II transport mechanism of drug 
permeation and erosion. On the other hand, SA06-PE (n 
= 0.97) had an anomalous transport mechanism favoring 
both diffusion and swelling (Siepmann, Peppas, 2012). 
An increase in flux was obtained by increasing DMSO 
concentration as shown in Table V.
The cumulative drug permeation for 7 : 3 (EL 100 : 
HPMC) polymeric system containing DMSO as permeation 
enhancer is shown in Figure 4. Drug permeation increased 
with increase in DMSO concentration, and the patches 
followed Higuchi model. The ‘n’ value of Korsmeyer-
Peppas equation indicated that SB04-PE, SB05-PE and 
SB06-PE had super case II transport mechanism with values 
greater than 1. The flux increased as the amount of DMSO 
concentration increased (Ali et al., 2016).
An increase in cumulative drug permeation was 
observed when the concentrations of HPMC and DMSO 
were increased. DMSO has been shown to change the 
intercellular keratin confirmation from α helical structure 
to β sheets, thereby denaturing proteins. It also interacts 
with the head group of some bilayer lipids to distort 
the packing geometry within the intercellular domain 
of human stratum corneum (Williams, Barry, 2012). 
Statistical results using the one-way ANOVA and Tukey 
multiple comparison test showed a significant difference 
in drug permeation rate at t10 and flux at different DMSO 
concentrations (p < 0.001, Shabbir et al., 2016).
CONCLUSION
Based on the results of the present study, it can 
be reasonably concluded that 7 : 3 ratio of EL-100 and 
TABLE V - Slope, flux and permeability coefficient of 
formulations containing permeation enhancer
Formulation Slope Flux (µg/cm2.h)
Permeability 
coefficient 
(cm/h)
SA01-B 27.84 23.20 0.0136
SB01-B 47.28 39.40 0.0232
SA01-PE 30.82 25.69 0.0151
SA02-PE 61.46 51.22 0.0301
SA03-PE 73.06 60.89 0.0354
SA04-PE 61.81 51.50 0.0303
SA05-PE 65.47 54.56 0.0327
SA06-PE 68.61 57.18 0.0336
SB01-PE 95.52 79.60 0.0468
SB02-PE 118.29 98.57 0.0580
SB03-PE 122.52 102.10 0.0606
SB04-PE 77.92 64.93 0.0382
SB05-PE 113.88 94.90 0.0558
SB06-PE 138.15 115.13 0.0677
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HPMC, with 15% Span 20, can be successfully prepared 
for the sustained release of TZD HCl. The drug release 
increases commensurately with increases in HPMC 
concentration, while EL-100 acts a retardant at high 
polymer concentration. The transdermal flux increases 
at higher Span 20 and DMSO concentrations. The 
highest permeation enhancement can be obtained with 
formulations containing 15% (w/w) Span 20. Maximum 
cumulative drug release with higher flux through skin 
can be achieved by SB03-PE at 95% CI. The formulation 
followed zero order kinetic model with Super case II 
transport mechanism of drug permeation.
REFERENCES
Ali S, Shabbir M, Shahid N, Amin U, Hamid I, Raza M. Effect 
of Polysorbate 80 through rabbit’s skin using transdermal patch 
loaded with bisoprolol fumarate as model drug. Pak J Zool. 
2016;48(1):227-34.
Ammar H, Ghorab M, El-Nahhas S, Kamel R. Polymeric matrix 
system for prolonged delivery of tramadol hydrochloride, 
part I: physicochemical evaluation. AAPS PharmSciTech. 
2009;10(1):7-20. 
Ansari K, Singhai A, Saraogi GK. Recent advancement 
in transdermal drug delivery system. Indian J Pharm Sci. 
2011;3(5):52-9.
Arora P, Mukherjee B. Design, development, physicochemical, 
in vitro and in vivo evaluation of transdermal patches 
containing diclofenac diethylammonium salt. J Pharm Sci-Us. 
2002;91(9):2076-89.
Costa P, Sousa L. Modeling and comparison of dissolution 
profiles. Eur J Pharm Sci. 2001;13(2):123-33. 
Darwhekar G, Jain DK, Patidar VK. Formulation and evaluation 
of transdermal drug delivery system of clopidogrel bisulfate. 
Asin J Pharmy Life Sci. 2011;1(3):269-278.
El-Gendy NA, Sabry NA, El-Attar M, Omar E, Mahmoud M. 
Transdermal patch incorporating salbutamol sulphate: In vitro and 
clinical characterization. Drug Discov Ther. 2008;2(4):219-28.
Eva S, Milan D. Pharmaceutical applications of plasticized 
polymers. In: Luqman M, (editor). Recent Advances in 
Plasticizers. 2012. InTech, DOI: 10.5772/36543. Available 
from:http://www.intechopen.com/books/recent-advances-
in-plasticizers/pharmaceutical-applications-of-plasticized-
polymers.
Gratieri T, Pujol-Bello E, Gelfuso GM, De-Souza JG, Lopez RF, 
Kalia YN. Iontophoretic transport kinetics of ketorolac in vitro 
and in vivo: demonstrating local enhanced topical drug delivery 
to muscle. Eur J Pharm Biopharm. 2014;86(2):219-26.
Janardhanan B, Ramachandra V, Rajappan M. Formulation 
development and in vitro and in vivo evaluation of membrane 
moderated transdermal systems of Ampicillin sodium in 
ethanol: pH 4.7 buffer solvent system. AAPS PharmSciTech. 
2007;8(1):E50-E55.
Jaydatt J, Sreenivas SA. Formulation and in vitro evaluation of 
drug reservoir transdermal patches of Piroxicam using polymers 
HPMC E15, PVP K30 and Eudragit L100. J Pharm Innov. 
2013;3(5):67-80.
Kamen L, Henney HR, Runyan JD. A practical overview 
of tizanidine use for spasticity secondary to multiple 
sclerosis, stroke, and spinal cord injury. Curr Med Res Opin. 
2008;24(2):425-39.
Kumar R, Philip A. Modified transdermal technologies: 
Breaking the barriers of drug permeation via the skin. Trop J 
Pharm Res. 2007;6(1):633-44.
Kusum DV, Saisivam S, Maria GR, Deepti PU. Design and 
evaluation of matrix diffusion controlled transdermal patches of 
verapamil hydrochloride. Drug Dev Ind Pharm. 2003;29(5):495-
503.
Limpongsa E, Umprayn K. Preparation and evaluation of 
Diltizem hydrochloride diffusion-controlled transdermal 
delivery system. AAPS PharmSciTech. 2008;9(2):464-470.
Mutalik S, Parekh HS, Davies NM, Nayanabhirama U. A 
combined approach of chemical enhancers and sonophoresis 
for the transdermal delivery of tizanidine hydrochloride. Drug 
Deliv. 2009;16(2):82-91.
Patel DP, Setty CM, Mistry GN, Patel SL, Patel TJ, Mistry PC, 
et al. Development and evaluation of ethyl cellulose-based 
transdermal films of furosemide for improved in vitro skin 
permeation. AAPS PharmSciTech. 2009;10(2):437-442.
Pathan IB, Setty CM. Chemical penetration enhancers 
for transdermal drug delivery systems. Trop J Pharm Res. 
2009;8(2):173-9.
M.. Shabbir, S. Ali, I. Hamid, A. Sharif, M. F. Akhtar, M. Raza, S. Ahmed, S. Peerzada, M. Umair Amin
Braz. J. Pharm. Sci. 2018;54(4):e00130Page 12 / 12
Perioli L, Ambrogi V, Venezia L, Giovagnoli S, Pagano C, 
Rossi C. Formulation studies of benzydamine mucoadhesive 
formulations for vaginal administration. Drug Dev Ind Pharm. 
2009;35(7):769-79.
Pichayakorn W, Susaeree J, Boonme P, Amnuaikit T, Taweepreda 
W, Ritthidej G, et al. Nicotine transdermal patches using 
polymeric natural rubber as the matrix controlling system: effct 
of polymer and plasticizer blends. J Membr Sci. 2012;411-
412:82-90.
Prabhakar D, Aparna C, Shastri N, Sadanandam M. Development 
of transdermal patches for Bisoprolol fumarate. J Pharm Res. 
2012;5(3):1338-41.
Prabu SL, Prakash TS, Thiyagarajan S, Amritha M, Manibharathi 
R, Priyadharsini N. Design and evaluation of matrix diffusion 
controlled transdermal patches of dexibuprofen. J Appl Res. 
2012;12(1):38-46.
Shabbir M, Ali S, Farooq M, Adnan S, Yousaf M, Idrees A, et 
al. Formulation factors affecting in vitro and ex vivo permeation 
of bisoprolol fumarate from a matrix transdermal patch. Adv. 
Polym. Technol. 2016;35(3):237-247.
Shabbir M, Fazli AR, Ali S, Raza M, Sharif A, Akhtar MF, et 
al. Effect of hydrophilic and hydrophobic polymer on in vitro 
dissolution and permeation of bisoprolol fumarate through 
transdermal patch. Acta Pol Pharm. 2017;74(1):187-197.
Shanker G, Kumar CK, Gonugunta CSR, Kumar BV, 
Veerareddy PR. Formulation and evaluation of bioadhesive 
buccal drug delivery of tizanidine hydrochloride tablets. AAPS 
Pharmscitech. 2009;10(2):530-9.
Shirsand S, Ladhane G, Prathap S, Prakash P. Design and 
evaluation of matrix transdermal patches of meloxicam. RGUHS 
J Pharm Sci. 2012;2(4):58-65.
Siepmann J, Peppas N. Modeling of drug release from delivery 
systems based on hydroxypropyl methylcellulose (HPMC). Adv 
Drug Deliver Rev. 2012;64:163-74.
Sintov AC, Botner S. Transdermal drug delivery using 
microemulsion and aqueous systems: influence of skin storage 
conditions on the in vitro permeability of diclofenac from 
aqueous vehicle systems. Int J Pharmaceut. 2006;311(1):55-62.
Ubaidulla U, Reddy M, Ruckmani K, Ahmad FJ, Khar RK. 
Transdermal therapeutic system of carvedilol: Effect of 
hydrophilic and hydrophobic matrix on in vitro and in vivo 
characteristics. AAPS PharmSciTech. 2007;8(1):E13-E20.
Xiangrong Z, Yanjiao W, Yan W, Sanming L. Effect of pore 
former on the properties of casted film prepared from blends of 
Eudragit NE 30 D and Eudragit L 30D-55. Chem Pharm Bull. 
2007;55(8):1261-1263.
Xi H, Yang Y, Zhao D, Fang L, Sun L, Mu L, et al. Transdermal 
pacthes for site-specific delivery of anastrazole: In vitro and 
local tissue disposition evaluation. Int J Pharmaceut. 2010; 
391(1):73-78.
Williams AC, Barry BW. Penetration enhancers. Adv Drug 
Deliver Rev. 2012;64:128-37.
Received for publication on 04th November 2016
Accepted for publication on 07th March 2018
This is an open-access article distributed under the terms of the Creative Commons Attribution License.
